» Speaking

Scott M. Lassman Speaks at FDLI Advertising and Promotion Conference

Scott M. Lassman participated in a panel discussion on October 28, 2020 regarding "FDA-FTC Biologics Promotion Enforcement" at the Food and Drug Law Institute's (FDLI) Advertising and Promotion for Medical Products Conference. Scott's presentation focused on the promotional implications of a recent patent infringement case, GlaxoSmithKline v. Teva, on biosimilars and interchangeable biologics.

Categories: Speaking

NEW, EMERGING AND CONTINUALLY INTERESTING BIOSIMILARS ISSUES

Scott M. Lassman gave a presentation on New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on October 15, 2020.

Categories: Speaking

Scott M. Lassman Speaks at FDLI's Annual Conference 2020

Scott M. Lassman participated in a panel discussion at FDLI's Annual Conference 2020 on October 6, 2020 regarding "Issues and Topics in Litigation Challenging FDA Actions under the Administrative Procedure Act (APA)." Scott's presentation focused on the evolving risks and benefits of challenging FDA actions on Chevron Step Two grounds.

Categories: Speaking

RAPS Convergence 2020 Session on the "Regulatory Strategy of Drug Competition"

Scott M. Lassman is scheduled to speak on September 16, 2020 at RAPS Convergence 2020 on a panel entitled The Regulatory Strategy of Drug Competition.

Categories: Speaking

WCL's Hot Topics in Drug and Medical Device Regulation

Scott M. Lassman will be participating in a panel discussion on June 19, 2020 on Hot Topics in Drug and Medical Device Regulation, which is part of Washington College of Law's Virtual Summer Series on Health Law and Policy (co-sponsored by the American Health Law Association). He will be presenting on new developments regarding orphan drug exclusivity.

Categories: Speaking

New, Emerging and Continually Interesting Biosimilars Issues

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.

Categories: Speaking

Exclusivity Webinar

On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Categories: Speaking

Biosimilars at the Bar

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Categories: Speaking

New Developments in Biologics and Biosimilars

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.

Categories: Speaking

Biosmilars

Scott Lassman spoke on Biosimilars at the Food and Drug Law Institute’s Introduction to Biologics and Biosimilars Conference in Washington, D.C.

Categories: Speaking

Scott Lassman

Scott M. Lassman's Profile Image
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...

Read More About Scott

For More Information

  • This field is for validation purposes and should be left unchanged.